Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Apr 16, 2014 Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine
Apr 7, 2014 Celldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data presented at AACR 2014
What's New

2012 Form 10-K

More →Featured Events
Nov 25, 2013
8:30 AM ET
Rindopepimut Phase 2 ReACT Program Update
Nov 7, 2013
8:30 AM ET
CDX-1127 Program Update
May 23, 2012
4:30 PM ET
Celldex Therapeutics, Inc. to Discuss Topline Results of Phase 2b EMERGE Study of CDX-011 Conference Call
Jan 23, 2012 Celldex Therapeutics, Inc. Research and Development Day
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 8, 2013 Form 10-Q View HTML View PDF 339.2 KB Add to Briefcase
Mar 3, 2014 Form 10-K View HTML View PDF 909.7 KB Add to Briefcase
Add to Briefcase = add file to Briefcase